Sonya Miller, MBBS, FFARCS, FANZCA, TauRx Therapeutics Ltd., Aberdeen, UK, discusses why a growing proportion of Alzheimer’s Disease therapeutic research has shifted to focus on targeting tau. For decades, research has been more focused on amyloid, given its fundamental role in the proposed amyloid cascade hypothesis, as well as the availability of ligands for amyloid-PET. However, it is now known that the load of amyloid does not strongly correlate with cognitive decline. In comparison, where tau is deposited and how much tau is present in the brain is directly correlated with cognitive decline. Therefore, as tau is the crucial driver of cognitive decline, more research is being undertaken into this specific protein. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
